ASSOCIATION OF BRCA2 POLYMORPHISM TO SCHIZOPHRENIA IN SAARC COUNTRIES: A SYSTEMATIC REVIEW

Schizophrenia is a complex disorder of polygenic inheritance with a lifetime prevalence of 5-10%. An external study showed that the role of BRCA2 is needed for the normal neurogenesis in mice. Another recent meta-analysis showed that genetic polymorphism of BRCA2 could increase susceptibility to schizophrenia. This study conducted the possible relationship between BRCA2 polymorphisms in schizophrenic patients in participating SAARC (South Asian Association of Regional Corporation) countries (Pakistan, India, Sri Lanka, Nepal, Bhutan, Maldives, Bangladesh and Afghanistan). While conducting this review, we collected data from eight SAARC countries. We collected that articles which were published from 1997 to 2020, using PubMed, and NCBI databases to amplify data about the association of BRCA2 polymorphism to schizophrenia patients in SAARC countries. Totally 24 studies were included in this review. We have additionally reviewed fewer studies from other than SAARC countries to support the evidence concerning this issue. Major studies from each SAARC country have identified novel and pathogenic mutations in BRCA2 but have not assessed on BRCA2 polymorphism within schizophrenia patients. Yet, there is no conclusive evidence found regarding the association of BRCA2 polymorphism to schizophrenia.